<DOC>
	<DOCNO>NCT02552667</DOCNO>
	<brief_summary>Efficacy safety HCP1102 capsule : A randomized , double-blind , active-controlled , multicenter phase 3 clinical trial .</brief_summary>
	<brief_title>Efficacy Safety HCP1102 Capsule</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Inclusion : Ageâ‰¥15 Mild moderate asthma patient allergic rhinitis Patient meet criterion rhinitis Patients understood content purpose trial sign informed consent form Patients capable willing write subject diary Patients agree maintain environment clinical trial Exclusion : Nonallergic rhinitis Severe asthma Other pulmonary disease ( pulmonary tuberculosis , COPD ) except Asthma Medical history hypertrophic cardiomyopathy , cancer , renal disease , Liver disease , cardiovascular disease , respiratory disease , endocrine disorder , CNS disorder effect safety Medical history gastrointestinal surgery gastrointestinal disorder effect drug absorption Alcohol abuse Drug abuse Genetic factor galactose intolerance Lapp lactase deficiency glucosegalactose malabsorption pregnant breastfeed woman men/women childbearing age n't use contraceptive Patient administer investigational product within 30 day Current smoker Judged inappropriate study investigator review reason</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic rhinitis</keyword>
</DOC>